NCT01910181View on ClinicalTrials.gov

A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

August 17, 2013

Primary Completion Date

October 22, 2013

Study Completion Date

April 20, 2018

Conditions
Malignant Melanoma
Interventions
DRUG

Vemurafenib

Participants will receive vemurafenib at a dose of 960 mg twice daily orally.

Trial Locations (2)

100142

Beijing Cancer Hospital, Beijing

510060

Sun Yet-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01910181 - A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma | Biotech Hunter | Biotech Hunter